Your browser doesn't support javascript.
loading
The Role of Autoantibody Testing in Modern Personalized Medicine.
Kayser, Cristiane; Dutra, Lívia Almeida; Dos Reis-Neto, Edgard Torres; Castro, Charlles Heldan de Moura; Fritzler, Marvin J; Andrade, Luis Eduardo C.
Affiliation
  • Kayser C; Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
  • Dutra LA; Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, Brazil.
  • Dos Reis-Neto ET; Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
  • Castro CHM; Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
  • Fritzler MJ; Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada.
  • Andrade LEC; Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br.
Clin Rev Allergy Immunol ; 63(2): 251-288, 2022 Oct.
Article in En | MEDLINE | ID: mdl-35244870
Personalized medicine (PM) aims individualized approach to prevention, diagnosis, and treatment. Precision Medicine applies the paradigm of PM by defining groups of individuals with akin characteristics. Often the two terms have been used interchangeably. The quest for PM has been advancing for centuries as traditional nosology classification defines groups of clinical conditions with relatively similar prognoses and treatment options. However, any individual is characterized by a unique set of multiple characteristics and therefore the achievement of PM implies the determination of myriad demographic, epidemiological, clinical, laboratory, and imaging parameters. The accelerated identification of numerous biological variables associated with diverse health conditions contributes to the fulfillment of one of the pre-requisites for PM. The advent of multiplex analytical platforms contributes to the determination of thousands of biological parameters using minute amounts of serum or other biological matrixes. Finally, big data analysis and machine learning contribute to the processing and integration of the multiplexed data at the individual level, allowing for the personalized definition of susceptibility, diagnosis, prognosis, prevention, and treatment. Autoantibodies are traditional biomarkers for autoimmune diseases and can contribute to PM in many aspects, including identification of individuals at risk, early diagnosis, disease sub-phenotyping, definition of prognosis, and treatment, as well as monitoring disease activity. Herein we address how autoantibodies can promote PM in autoimmune diseases using the examples of systemic lupus erythematosus, antiphospholipid syndrome, rheumatoid arthritis, Sjögren syndrome, systemic sclerosis, idiopathic inflammatory myopathies, autoimmune hepatitis, primary biliary cholangitis, and autoimmune neurologic diseases.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoimmune Diseases / Sjogren's Syndrome / Lupus Erythematosus, Systemic Type of study: Prognostic_studies / Screening_studies Limits: Humans Language: En Journal: Clin Rev Allergy Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2022 Document type: Article Affiliation country: Brazil Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Autoimmune Diseases / Sjogren's Syndrome / Lupus Erythematosus, Systemic Type of study: Prognostic_studies / Screening_studies Limits: Humans Language: En Journal: Clin Rev Allergy Immunol Journal subject: ALERGIA E IMUNOLOGIA Year: 2022 Document type: Article Affiliation country: Brazil Country of publication: United States